Investigated for treating COVID-19.
Contra-indicated in patients with severe renal impairment, end-stage renal disease, or undergoing dialysis.
Qtern is dapagliflozin and saxagliptin; Xigduo XR is dapagliflozin and metformin.
- TRADE NAMES: Farxiga (AstraZeneca); Qtern (AstraZeneca); Xigduo XR (AstraZeneca)
- INDICATIONS: Type II diabetes mellitus
- CLASS: Antidiabetic, Sodium-glucose co-transporter 2 (SGLT2) inhibitor ('gliflozin')
- HALF-LIFE: 13 hours
- FDA APPROVAL DATE: 01/08/2014
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Pioglitazone
- See adverse reactions attributed to class:
Sodium-glucose co-transporter 2 (SGLT2) inhibitor ('gliflozin')
Please login to view the rest of this drug profile.
Page last updated 12/12/2025
